Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib 24 mg vs 10 mg in RAIR Differentiated Thyroid Cancer
NCT07092514Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in thyroid cancer, sponsored by Washington University School of Medicine. Started Oct 2025; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT07092514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07092514.